A Single-arm, Multi-center, Phase II Study of Tislelizumab, Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gemcitabine (Primary) ; Lenvatinib (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
Focus Therapeutic Use

28 Feb 2024 New trial record
20 Jan 2024 Results of primary analysis (At cut-off date September 10, 2023), presented at the 2024 Gastrointestinal Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com